Insulin resistance and atherosclerosis. The impact of oxidative stress on endothelial function;Resistencia a la insulina y aterosclerosis. Impacto del estrés oxidativo en la función endotelial

Revista Espanola de Cardiologia Suplementos

Volumn 8, Issue C, 2008, Pages

  Fernández Real, José Manuel ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Atherosclerosis; Cytokines; Inflammation; Insulin resistance; Iron

Indexed keywords

APOFERRITIN; CHOLESTEROL; CYTOKINE; DEFEROXAMINE; FERRITIN; FERROUS GLUCONATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; ENDOTHELIAL DYSFUNCTION; FERRITIN BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; IRON DEPLETION; IRON METABOLISM; NONHUMAN; OXIDATIVE STRESS; REVIEW; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION;

EID: 44449112640     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(08)73554-4     Document Type: Article

References (76)

1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-4.
2. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816-23.
3. van Gaal LF, Mertens IL, deBlock CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-80.
4. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26:1589-96.
5. Reif DW. Ferritin as a source of iron for oxidative damage. Free Rad Biol Med. 1992;12:417-27.
6. Fujimoto S, Kawakami N, Ohara A. Nonenzymatic glycation of transferrin: Decrease of Iron-binding capacity and increase of oxygen radical production. Biol Pharm Bull. 1995;18:396-400.
7. Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol. 1995;147:782-9.
8. O'Brien T, Basset B, Burray DM, Dinneen S, O'Sullivan DJ. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care. 1990;13:532-4.
9. Fernández-Real JM, Ricart W, Arroyo E, Balança R, Casamitjana R Cabrero D, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998;21:62-8.
10. Bertelsen M, Änggard EE, Carrier MJ. Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia. 2001;44:605-13.
11. Hirayama M, Kohgo Y, Kondo H, Shintani N, Fujikawa K, Sasaki K, et al: Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron. Hepatology. 1993;18:874-80.
12. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154-9.
13. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-7.
14. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-30.
15. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51:2348-54.
16. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:295-9.
17. Thomas CE, Morehouse LA Aust SD. Ferritin and superoxide-dependent lipid peroxidation. J Biol Chem. 1985;260:3275-80.
18. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, et al. Pre-B-cell colony-enhancing factor, whose expression is upregulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32:3225-34.
19. Fernandez-Real JM, Moreno JM, Chico B, Lopez-Bermejo A, Ricart W. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care. 2007;30:616-21.
20. Graier WF, Simecek S, Kukovetz WR, Kostner GM. High D-glucose-induced changes in endothelial Ca2+/EDRF signaling are due to generation of superoxide anions. Diabetes. 1996;45:1386-95.
21. Yue DKS, McLennon S, Fisher E, Heffernan S, Capogreco C, Ross GR. Ascorbic acid status and polyol pathway in diabetes. Diabetes. 1989;38:257-61.
22. Abdalla DSP, Campa A, Monteiro MP. Low density lipoprotein oxidation by stimulated neutrophils and ferritin. Atherosclerosis. 1992;97:149-59.
23. Lekakis J, Papamicheal C, Stamatelopoulos K, Cimponeriu A, Voutsas A, et al. Hemochromatosis associated with endothelial dysfunction: evidence for the role of iron stores in early atherogenesis. Vasc Med. 1999;4:147-8.
24. Araujo JA, Romano EL, Brito BE, Parthe V, Romano M, Bracho M, et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1172-80.
25. Pang J, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest. 1996;97:2204-12.
26. Failla M, Giannattasio C, Piperno A, Vergani A, Grappiolo A, Gentile G, et al. Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology. 2000;32:569-73.
27. Porreca E, Ucchino S, di Febbo C, di Bartolomeo N, Angelucci D, Napolitano AM, et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1994;14:299-304.
28. Pieper GM, Siebeneich W. Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J Cardiovasc Pharmacol. 1997;30:734-8.
29. Nitenberg A, Ledoux S, Valensi P, Sachs R, Antony I. Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients. Diabetes. 2002;51:813-8.
30. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce Jr JK. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-804.
31. Fernandez-Real JM, Peñarroja G, Castro A, Garcia-Bragado F, Ricart W. Blood letting in high-ferritin type 2 diabetes mellitus. Effects on vascular reactivity. Diabetes Care. 2002;25:2249-55.
32. Cameron NE, Cotter MA. Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia. 2001;44:621-8.
33. Angulo J, Sanchez-Ferrer CF, Peiro C, Marin J, Rodriguez-Mañas L. Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin: possible mechanisms involved. Hypertension. 1996;28:583-92.
34. Valk Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 1999;159:1542-8.
35. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
36. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45:623-34.
37. Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006;55:1133-40.
38. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-60.
39. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
40. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol. 2005;288:1016-21.
41. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
42. Ridker PM, Rifai N, Pfeffer M, Saks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor- alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2002;101:2149-53.
43. Engstrom G, Hedblad B, Stavenow L, Tyden P, Lind P, Janzon L, et al. Fatality of future coronary events is related to inflammation-sensitive plasma proteins: a population-based prospective cohort study. Circulation. 2004;110:27-31.
44. Pradham Ad, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifi N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980-7.
45. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72.
46. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary mechanism. Clin Nutr. 2005;24:16-31.
47. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-14.
48. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-34.
49. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1-78.
50. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-200.
51. Esteve E, Castro A, Lopez-Bermejo A, Vendrell J, Ricart W, Fernandez-Real JM. Serum interleukin 6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care. 2007;30:939-45.
52. Loppnow H, Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res. 1989;8:293-9.
53. Verma S, Wang Ch, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-9.
54. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM, Lipinska I, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation. 2004;110:3604-9.
55. Lee K, Blann AD, Lip GY. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Int J Cardiol. 2006;111:302-8.
56. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis. 2003;169:283-91.
57. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006;29:1071-6.
58. Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C. Tumor necrosis factor-a inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation. 2003;108:1815-21.
59. Chia S, Qadan M, Newton R, Ludlam C, Fox KA, Newby DE. Intra-arterial tumor necrosis factor-a impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol. 2003;23:695-701.
60. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Inmunol. 1986;137:3295-8.
61. Yoshizumi M, Perrella Ma, Burnett JC. Lee ME. Tumor necrosis factor downregulates an endotelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205-9.
62. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-7.
63. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-9.
64. Selinsky CL, Boroughs KL, Halsey WA, Howel MD. Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumor necrosis factor receptor type I. Inmunology. 1998;94:88-93.
65. Sugano M, Hata T, Tsuchida K, Suematsu N, Oyama J, Satoh S, et al. Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats. Mol Cell Biochem. 2004;206:127-32.
66. Sugano M, Tsuchida K, Hata T, Makino N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J. 2004;18:911-3.
67. Sugano M, Tsuchida K, Makino N. Increased proliferation of endothelial cells with overexpression of soluble TNF-alpha receptor I gene. Atherosclerosis. 2002;162:77-84.
68. Benjafield AV, Wang XL, Morris BJ. Tumor necrosis factor receptor 2 gene(TNFRSF1b) in genetic basis of coronary artery disease. J Mol Med. 2001;79:109-15.
69. Dzienis-Straczkowska S, Straczkowski M, Szelachowska M, Stepien A, Kowalska I, Kinalska I. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care. 2003;26:875-80.
70. Fernandez-Real JM, Lainez B, Vendrell J, Rigla M, Castro A, Peñarroja G, et al. Shedding of TNF-alpha receptors, blood pressure, and insulin sensitivity in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;282:952-9.
71. Aderka D, Engelmann H, Abu-Avid S, Lev D, Setton A, Cope AP, et al. Shedding kinetics of soluble tumor necrosis factor(TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest. 1998;101:650-9.
72. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNFR.) in organ inflammation independent of TNF, lymphotoxin a, or the p55TNFR. J Exp Med. 1998;188:1343-52.
73. Esteve E, Castro A, López-Bemejo A, Ricart W, Fernandez-Real JM. Divergent relationships among soluble TNF-alpha receptor 1 and 2, insulin resistance and endothelial function. Diabetes Care. 2006;29:1460-1.
74. Schreyer SA, Peschon JJ, leBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem. 1996;271:26174-8.
75. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, et al. Inhibition of NF-ÎB activation in macrophages increases atherosclerosis in LDL-receptor-deficient mice. J Clin Invest. 2003;112:1176-85.
76. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2005;116:1813-22.